Search - tctmd.com

Displaying 141 - 160 of 334

Sort: Relevancy | Date

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Bernard Chevalier

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

News Conference News TCT 2015

Absorb BVS Matches Xience V in Chinese Patients

Todd Neale

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

Presentation TCT 2015

I Want to Treat Vulnerable Plaques: Not Today but Tomorrow (From PROSPECT to PROSPECT ABSORB)

Presenter: Gary S. Mintz, Seung-Jung Park, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Rationale for and Design of HORIZONS-ABSORB

Presenter: Dariusz Dudek, Robert J. de Winter, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

BRS Results to Date: Imaging, Randomized Trials, and Anticipation of ABSORB III

Presenter: Thomas H. Maloney, David G. Rizik

October 11, 2015

Presentation TCT 2015

France Presents: French Absorb Registry Indications and In-Hospital Results

Presenter: George D. Dangas, Eric Van Belle, René Koning

October 11, 2015

News Conference News TCT 2015

Novel Devices Present New Treatment Options for STEMI

Yael L. Maxwell

October 11, 2015

News Opinion Editor's Corner

Editor's Corner: What to Expect at TCT 2015

Caitlin E. Cox

October 05, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Daily News

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Yael L. Maxwell

October 02, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

ABSORB Trials Pit BRS Against Second-Generation DES

Caitlin E. Cox

September 02, 2015

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

Advertisement

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Absorb BVS Matches Xience V in Chinese Patients

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

I Want to Treat Vulnerable Plaques: Not Today but Tomorrow (From PROSPECT to PROSPECT ABSORB)

Rationale for and Design of HORIZONS-ABSORB

BRS Results to Date: Imaging, Randomized Trials, and Anticipation of ABSORB III

France Presents: French Absorb Registry Indications and In-Hospital Results

Novel Devices Present New Treatment Options for STEMI

Editor's Corner: What to Expect at TCT 2015

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

ABSORB Trials Pit BRS Against Second-Generation DES

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content